INM
InMed Pharmaceuticals Inc
$
2.220
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
2.230
Open
2.210
VWAP
2.18
Vol
26.81K
Mkt Cap
4.44M
Low
2.170
Amount
58.44K
EV/EBITDA(TTM)
--
Total Shares
8.36M
EV
-275.56K
EV/OCF(TTM)
--
P/S(TTM)
0.26
InMed Pharmaceuticals Inc. is a pharmaceutical company. The Company develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharma segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is a small molecule drug candidate being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2024Q4
1.78M
-22.48%
--
--
Estimates Revision
The market is revising No Change the revenue expectations for InMed Pharmaceuticals Inc. (INM) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -35.09%.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Down
-35.09%
In Past 3 Month
Valuation Metrics
The current forward P/E ratio for InMed Pharmaceuticals Inc (INM.O) is -0.02, compared to its 5-year average forward P/E of -0.99. For a more detailed relative valuation and DCF analysis to assess InMed Pharmaceuticals Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-0.99
Current PE
-0.02
Overvalued PE
0.24
Undervalued PE
-2.22
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-0.41
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.45
Undervalued EV/EBITDA
-1.27
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
2.55
Current PS
0.67
Overvalued PS
7.79
Undervalued PS
-2.68
Financials
Annual
Quarterly
FY2025Q3
YoY :
+7.59%
1.26M
Total Revenue
FY2025Q3
YoY :
+17.77%
-2.12M
Operating Profit
FY2025Q3
YoY :
+23.10%
-2.12M
Net Income after Tax
FY2025Q3
YoY :
-45.81%
-1.94
EPS - Diluted
FY2025Q3
YoY :
-14.21%
-1.66M
Free Cash Flow
FY2025Q3
YoY :
-71.86%
5.63
Gross Profit Margin - %
FY2025Q3
YoY :
+18.26%
-142.61
FCF Margin - %
FY2025Q3
YoY :
+14.42%
-168.12
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
INM News & Events
Events Timeline
2025-06-25 (ET)
2025-06-25
08:13:17
InMed Pharmaceuticals announces $5M private placement
2025-06-24 (ET)
2025-06-24
07:41:33
InMed Pharmaceuticals announces new preclinical data on INM-901
2025-02-12 (ET)
2025-02-12
18:02:45
InMed Pharmaceuticals reports Q2 EPS ($3.64) vs ($3.71) last year
Sign Up For More Events
Sign Up For More Events
News
9.0
07-04BenzingaCognition Therapeutics Shares Jump 12% After Hours Following Encouraging Phase 2 Alzheimer's Trial Data
9.0
06-24BenzingaWhy InMed's Alzheimer's Drug Candidate Is Fueling Sudden Stock Surge
2.0
06-03TipRanks3 Penny Stocks to Watch Now, 6/3/25
Sign Up For More News
People Also Watch
FAQ
What is InMed Pharmaceuticals Inc (INM) stock price today?
The current price of INM is 2.22 USD — it has increased 1.83 % in the last trading day.
What is InMed Pharmaceuticals Inc (INM)'s business?
What is the price predicton of INM Stock?
What is InMed Pharmaceuticals Inc (INM)'s revenue for the last quarter?
What is InMed Pharmaceuticals Inc (INM)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for InMed Pharmaceuticals Inc (INM)'s fundamentals?
How many employees does InMed Pharmaceuticals Inc (INM). have?